Charmaine R. Rock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Charmaine R. Rock has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Beth Joyce Allison
The Ritchie Centre, Hudson Institute of Medical Research, Clayton, Australia
6 shared publications - Suzanne L. Miller
The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia; Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia
4 shared publications - Amy Elizabeth Sutherland
The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia
3 shared publications Beth R. Piscopo
The Ritchie Centre Hudson Institute of Medical Research Clayton VIC Australia
3 shared publicationsYen Pham
Hudson Institute of Medical Research
3 shared publicationsAmy E. Sutherland
Hudson Institute of Medical Research
2 shared publications
Latest Publications
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 329 (6) , H1633-H1645
Untargeted metabolomics identifies altered cardiac metabolite and gene expression patterns in late preterm growth-restricted newborn lambs
Within 24 h of birth, growth-restricted (FGR) newborn lambs exhibited altered lipid and serotonin metabolites, suggesting disrupted postnatal cardiac metabolic adaptation. Despite upregulation of the fatty acid transporter gene SLC27A6, with other fatty acid oxidation genes remaining largely unchanged, reductions in lipid and carnitine metabolites indicate potential impairments in fatty acid utilization. Decreased serotonin bioavailability further suggests metabolic reprogramming in FGR hearts, highlighting the need for future studies on the implications for postnatal cardiac function.
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 329 (6) , H1633-H1645
Untargeted metabolomics identifies altered cardiac metabolite and gene expression patterns in late preterm growth-restricted newborn lambs
Within 24 h of birth, growth-restricted (FGR) newborn lambs exhibited altered lipid and serotonin metabolites, suggesting disrupted postnatal cardiac metabolic adaptation. Despite upregulation of the fatty acid transporter gene SLC27A6, with other fatty acid oxidation genes remaining largely unchanged, reductions in lipid and carnitine metabolites indicate potential impairments in fatty acid utilization. Decreased serotonin bioavailability further suggests metabolic reprogramming in FGR hearts, highlighting the need for future studies on the implications for postnatal cardiac function.
- Open Access
- 13 November 2025
- Published by Wiley in The Journal of Physiology
- Vol. 604 (1) , 193-213
Antenatal melatonin for cardiovascular deficits in fetal growth restriction
Fetal growth restriction (FGR) increases the risk of cardiovascular disease. FGR is linked to placental insufficiency and fetal hypoxemia, leading to oxidative stress and inflammation, which collectively influence the developmental programming of cardiovascular disease. This study assessed whether melatonin (MLT), a potent antioxidant and anti‐inflammatory agent, could prevent cardiovascular deficits associated with FGR. Placental insufficiency was induced in ewes at 89 days of gestational age (dGA, term 148 dGA). Ewes were randomly allocated to control, FGR or FGR+MLT ( i.v. , 15 mg day −1 , from 95 dGA to birth) groups. Lambs were delivered preterm at 136 dGA and assessed as newborn (24 h) and 4‐week‐old lambs. Vascular function was determined in femoral arteries using in vitro wire myography and vascular morphology as assessed in carotid and femoral arteries. Newborn FGR lambs were ∼30% smaller than control lambs with an increased brain‐to‐body weight ratio, indicative of brain sparing. Femoral endothelial function declined between ∼24 h after birth and 4 weeks in FGR lambs. By contrast, femoral arteries from newborn FGR+MLT lambs displayed transient endothelial dysfunction that improved by 4 weeks. However, these arteries showed elevated levels of oxidative stress and inflammation. Despite improving endothelial function, melatonin also disrupted the brain‐sparing response in FGR lambs. Furthermore, by 4 weeks of age, melatonin treatment led to heightened oxidative stress and inflammatory markers in the peripheral vasculature, suggesting a potential trade‐off between vascular benefits and systemic maladaptation. These findings highlight the complexity of melatonin's effects on the cardiovascular system and underscore the need for careful evaluation of its long‐term safety and efficacy before clinical translation. image Key points: Fetal growth restriction (FGR) significantly increases the lifelong risk of cardiovascular disease, and there are currently no targeted treatments to mitigate these risks. This study follows growth‐restricted lambs from birth to 4 weeks of age (comparable to a 1‐year‐old human in terms of cardiovascular function) to characterise how FGR affects vascular development over time. FGR lambs exhibited progressive endothelial dysfunction in the femoral artery, but antenatal melatonin treatment restored endothelial function long‐term despite the presence of vascular oxidative stress and inflammation. The brain‐sparing response is a key adaptive mechanism for fetal survival, yet melatonin appears to dampen this response, highlighting the need for further investigation into its broader physiological effects.
- 13 November 2025
- Published by Wiley in The Journal of Physiology
- Vol. 604 (1) , 193-213
Open AccessAntenatal melatonin for cardiovascular deficits in fetal growth restriction
Fetal growth restriction (FGR) increases the risk of cardiovascular disease. FGR is linked to placental insufficiency and fetal hypoxemia, leading to oxidative stress and inflammation, which collectively influence the developmental programming of cardiovascular disease. This study assessed whether melatonin (MLT), a potent antioxidant and anti‐inflammatory agent, could prevent cardiovascular deficits associated with FGR. Placental insufficiency was induced in ewes at 89 days of gestational age (dGA, term 148 dGA). Ewes were randomly allocated to control, FGR or FGR+MLT ( i.v. , 15 mg day −1 , from 95 dGA to birth) groups. Lambs were delivered preterm at 136 dGA and assessed as newborn (24 h) and 4‐week‐old lambs. Vascular function was determined in femoral arteries using in vitro wire myography and vascular morphology as assessed in carotid and femoral arteries. Newborn FGR lambs were ∼30% smaller than control lambs with an increased brain‐to‐body weight ratio, indicative of brain sparing. Femoral endothelial function declined between ∼24 h after birth and 4 weeks in FGR lambs. By contrast, femoral arteries from newborn FGR+MLT lambs displayed transient endothelial dysfunction that improved by 4 weeks. However, these arteries showed elevated levels of oxidative stress and inflammation. Despite improving endothelial function, melatonin also disrupted the brain‐sparing response in FGR lambs. Furthermore, by 4 weeks of age, melatonin treatment led to heightened oxidative stress and inflammatory markers in the peripheral vasculature, suggesting a potential trade‐off between vascular benefits and systemic maladaptation. These findings highlight the complexity of melatonin's effects on the cardiovascular system and underscore the need for careful evaluation of its long‐term safety and efficacy before clinical translation. image Key points: Fetal growth restriction (FGR) significantly increases the lifelong risk of cardiovascular disease, and there are currently no targeted treatments to mitigate these risks. This study follows growth‐restricted lambs from birth to 4 weeks of age (comparable to a 1‐year‐old human in terms of cardiovascular function) to characterise how FGR affects vascular development over time. FGR lambs exhibited progressive endothelial dysfunction in the femoral artery, but antenatal melatonin treatment restored endothelial function long‐term despite the presence of vascular oxidative stress and inflammation. The brain‐sparing response is a key adaptive mechanism for fetal survival, yet melatonin appears to dampen this response, highlighting the need for further investigation into its broader physiological effects.
- Open Access
- 24 July 2025
- Published by Elsevier in Experimental Neurology
- Vol. 393, 115397
Persistent inflammation and white matter damage in the preterm brain: Insights from a novel ovine model of chronic inflammation
- 24 July 2025
- Published by Elsevier in Experimental Neurology
- Vol. 393, 115397
Open AccessPersistent inflammation and white matter damage in the preterm brain: Insights from a novel ovine model of chronic inflammation
- Open Access
- 15 November 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (11) , 1400
The Use of Antioxidants for Cardiovascular Protection in Fetal Growth Restriction: A Systematic Review
Fetal growth restriction (FGR) increases the risk of cardiovascular disease. There are currently no treatment options available; however, antioxidants have shown potential to improve cardiovascular deficits associated with FGR. This systematic review aimed to determine whether antenatal antioxidant intervention can effectively protect the developing cardiovascular system in FGR. We searched for interventional studies that used an antenatal antioxidant intervention to improve cardiac and/or vascular outcomes in FGR published between 01/1946 and 09/2024 using MEDLINE and Embase (PROSPERO: CRD42024503756). The risk of bias was assessed with SYRCLE. The studies were assessed for cardiovascular protection based on the percentage of cardiac and/or vascular deficits that were restored with the antioxidant treatment. Studies were characterised as showing strong cardiovascular protection (≥50% restoration), mild cardiovascular protection (>0% but antioxidant-only effect (this did not include control group which showed a change with antioxidant intervention compared to FGR) or no cardiovascular protection (0% restoration). Thirty-eight publications met the inclusion criteria, encompassing 43 studies and investigating 15 antioxidant interventions. Moreover, 29/43 studies (71%) reported the restoration of at least one cardiac or vascular deficit with antioxidant intervention, and 21/43 studies (51%) were classified as strong cardiovascular protection. An ex vivo analysis of the arterial function in seven studies revealed endothelial dysfunction in growth-restricted offspring and antioxidant interventions restored the endothelial function in all cases. Additionally, four studies demonstrated that antioxidants reduced peroxynitrite-mediated oxidative stress. Notably, only 13/43 studies (32%) delayed antioxidant administration until after the induction of FGR. Antenatal antioxidant interventions show promise for providing cardiovascular protection in FGR. Melatonin was the most frequently studied intervention followed by nMitoQ, vitamin C and N-acetylcysteine, all of which demonstrated a strong capacity to reduce oxidative stress and improve nitric oxide bioavailability in the cardiovascular system of growth-restricted offspring; however, this systematic review highlights critical knowledge gaps and inconsistencies in preclinical research, which hinder our ability to determine which antioxidant treatments are currently suitable for clinical translation.
- 15 November 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (11) , 1400
Open AccessThe Use of Antioxidants for Cardiovascular Protection in Fetal Growth Restriction: A Systematic Review
Fetal growth restriction (FGR) increases the risk of cardiovascular disease. There are currently no treatment options available; however, antioxidants have shown potential to improve cardiovascular deficits associated with FGR. This systematic review aimed to determine whether antenatal antioxidant intervention can effectively protect the developing cardiovascular system in FGR. We searched for interventional studies that used an antenatal antioxidant intervention to improve cardiac and/or vascular outcomes in FGR published between 01/1946 and 09/2024 using MEDLINE and Embase (PROSPERO: CRD42024503756). The risk of bias was assessed with SYRCLE. The studies were assessed for cardiovascular protection based on the percentage of cardiac and/or vascular deficits that were restored with the antioxidant treatment. Studies were characterised as showing strong cardiovascular protection (≥50% restoration), mild cardiovascular protection (>0% but antioxidant-only effect (this did not include control group which showed a change with antioxidant intervention compared to FGR) or no cardiovascular protection (0% restoration). Thirty-eight publications met the inclusion criteria, encompassing 43 studies and investigating 15 antioxidant interventions. Moreover, 29/43 studies (71%) reported the restoration of at least one cardiac or vascular deficit with antioxidant intervention, and 21/43 studies (51%) were classified as strong cardiovascular protection. An ex vivo analysis of the arterial function in seven studies revealed endothelial dysfunction in growth-restricted offspring and antioxidant interventions restored the endothelial function in all cases. Additionally, four studies demonstrated that antioxidants reduced peroxynitrite-mediated oxidative stress. Notably, only 13/43 studies (32%) delayed antioxidant administration until after the induction of FGR. Antenatal antioxidant interventions show promise for providing cardiovascular protection in FGR. Melatonin was the most frequently studied intervention followed by nMitoQ, vitamin C and N-acetylcysteine, all of which demonstrated a strong capacity to reduce oxidative stress and improve nitric oxide bioavailability in the cardiovascular system of growth-restricted offspring; however, this systematic review highlights critical knowledge gaps and inconsistencies in preclinical research, which hinder our ability to determine which antioxidant treatments are currently suitable for clinical translation.
- 1 December 2023
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 325 (6) , H1266-H1278
Cardiovascular decline in offspring during the perinatal period in an ovine model of fetal growth restriction
Our findings provide novel insight into the potential mechanisms that program for cardiovascular dysfunction in growth-restricted neonates as our growth-restricted lambs exhibited a progressive decline in endothelium-dependent vasodilation in the femoral artery between birth and 4 wk of age. Subsequent analyses indicated that this reduction in vasodilatory capacity is likely to be mediated by the prostanoid pathway and prostanoids could be a potential target for therapeutic interventions for fetal growth restriction (FGR).
- 1 December 2023
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 325 (6) , H1266-H1278
Cardiovascular decline in offspring during the perinatal period in an ovine model of fetal growth restriction
Our findings provide novel insight into the potential mechanisms that program for cardiovascular dysfunction in growth-restricted neonates as our growth-restricted lambs exhibited a progressive decline in endothelium-dependent vasodilation in the femoral artery between birth and 4 wk of age. Subsequent analyses indicated that this reduction in vasodilatory capacity is likely to be mediated by the prostanoid pathway and prostanoids could be a potential target for therapeutic interventions for fetal growth restriction (FGR).
- Open Access
- 14 July 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (14)
Cardiovascular and Cerebrovascular Implications of Growth Restriction: Mechanisms and Potential Treatments
Fetal growth restriction (FGR) is a common complication of pregnancy, resulting in a fetus that fails to reach its genetically determined growth potential. Whilst the fetal cardiovascular response to acute hypoxia is well established, the fetal defence to chronic hypoxia is not well understood due to experiment constraints. Growth restriction results primarily from reduced oxygen and nutrient supply to the developing fetus, resulting in chronic hypoxia. The fetus adapts to chronic hypoxia by redistributing cardiac output via brain sparing in an attempt to preserve function in the developing brain. This review highlights the impact of brain sparing on the developing fetal cardiovascular and cerebrovascular systems, as well as emerging long-term effects in offspring that were growth restricted at birth. Here, we explore the pathogenesis associated with brain sparing within the cerebrovascular system. An increased understanding of the mechanistic pathways will be critical to preventing neuropathological outcomes, including motor dysfunction such as cerebral palsy, or behaviour dysfunctions including autism and attention-deficit/hyperactivity disorder (ADHD).
- 14 July 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (14)
Open AccessCardiovascular and Cerebrovascular Implications of Growth Restriction: Mechanisms and Potential Treatments
Fetal growth restriction (FGR) is a common complication of pregnancy, resulting in a fetus that fails to reach its genetically determined growth potential. Whilst the fetal cardiovascular response to acute hypoxia is well established, the fetal defence to chronic hypoxia is not well understood due to experiment constraints. Growth restriction results primarily from reduced oxygen and nutrient supply to the developing fetus, resulting in chronic hypoxia. The fetus adapts to chronic hypoxia by redistributing cardiac output via brain sparing in an attempt to preserve function in the developing brain. This review highlights the impact of brain sparing on the developing fetal cardiovascular and cerebrovascular systems, as well as emerging long-term effects in offspring that were growth restricted at birth. Here, we explore the pathogenesis associated with brain sparing within the cerebrovascular system. An increased understanding of the mechanistic pathways will be critical to preventing neuropathological outcomes, including motor dysfunction such as cerebral palsy, or behaviour dysfunctions including autism and attention-deficit/hyperactivity disorder (ADHD).